The New Wave of Glucagon-Based Weight Loss Drugs: From Single to Triple Receptor Agonists
Glucagon-based therapies — including dual and triple receptor agonists — represent the next frontier in obesity treatment, with each added receptor target potentially amplifying weight loss.
Quick Facts
What This Study Found
This review maps the full landscape of glucagon-based obesity therapies, from single-receptor agonists to the newest triple-agonist drugs. Glucagon — traditionally seen as a blood-sugar-raising hormone — is being reframed as a metabolic multitool that boosts energy expenditure, suppresses appetite, and promotes fat burning.
The review covers single glucagon receptor agonists, dual agonists (GLP-1/glucagon like survodutide, and GLP-1/GIP like tirzepatide), and the emerging triple agonists that target GLP-1, GIP, and glucagon receptors simultaneously (like retatrutide). It also discusses combination approaches involving amylin, thyroid hormone (T3), FGF21, and peptide YY. Triple agonists show the most potent weight loss in early trials, leveraging the additive metabolic benefits of activating all three receptor pathways.
Key Numbers
How They Did This
Narrative review summarizing preclinical and clinical findings on glucagon-based obesity therapies, including single, dual, and triple receptor agonists, with discussion of mechanism of action, safety profiles, and ongoing clinical trials.
Why This Research Matters
The obesity drug pipeline is rapidly evolving from single-target GLP-1 drugs (semaglutide) to multi-receptor agonists. Understanding why glucagon — a hormone that raises blood sugar — can paradoxically help with weight loss is key to understanding the next generation of metabolic drugs. This review provides a comprehensive map of where the field is heading, explaining why adding glucagon receptor activation to GLP-1 therapy may produce superior weight loss through increased energy expenditure.
The Bigger Picture
We're witnessing a rapid evolution in metabolic drug design: from single GLP-1 agonists to dual and triple agonists within just a few years. The inclusion of glucagon receptor activation is a paradigm shift — using a hormone traditionally associated with raising blood sugar for weight management. This 'more receptors, more weight loss' approach is driving the pipeline toward drugs like retatrutide (GLP-1/GIP/glucagon triple agonist) that have shown unprecedented weight loss in early trials.
What This Study Doesn't Tell Us
This is a narrative review without systematic search methodology or meta-analysis. Many of the therapies discussed are in early clinical development, so long-term safety and efficacy data are limited. The review may not capture the most recent trial results published after its preparation.
Questions This Raises
- ?Will triple agonists like retatrutide maintain their weight loss advantage over dual agonists in large phase 3 trials?
- ?Can the blood-sugar-raising effect of glucagon receptor activation be safely managed in patients with diabetes?
- ?Is there a ceiling to the 'more receptors, more weight loss' approach, or will quad-agonists eventually emerge?
Trust & Context
- Key Stat:
- Single → Dual → Triple agonists The progression from GLP-1 alone to dual (GLP-1/GIP or GLP-1/glucagon) to triple (GLP-1/GIP/glucagon) agonism reflects the evolving strategy of combining receptor targets for greater metabolic impact.
- Evidence Grade:
- This is a narrative review that synthesizes preclinical and clinical literature. It provides a useful overview of the field but does not present new data or use systematic methodology.
- Study Age:
- Published in 2024. This is a current and timely overview, though the field is moving rapidly and some drugs discussed may have updated trial data since publication.
- Original Title:
- Innovative Glucagon-based Therapies for Obesity.
- Published In:
- Journal of the Endocrine Society, 8(12), bvae197 (2024)
- Authors:
- Enyew Belay, Kibret, Jemal, Rebil Heiru, Tuyizere, Aloys
- Database ID:
- RPEP-08163
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why would adding glucagon help with weight loss when glucagon raises blood sugar?
Glucagon does raise blood sugar, but it also increases energy expenditure (calorie burning), promotes fat breakdown, and may reduce appetite. When combined with GLP-1 (which lowers blood sugar and suppresses appetite), the blood sugar effects can be balanced while the weight loss effects are amplified. The net result is more weight loss than GLP-1 alone.
What's the difference between a dual and triple agonist weight loss drug?
A dual agonist activates two hormone receptors — like tirzepatide (GLP-1 + GIP) or survodutide (GLP-1 + glucagon). A triple agonist like retatrutide activates three at once (GLP-1 + GIP + glucagon). Each additional receptor target adds another metabolic pathway, which appears to produce more weight loss in clinical trials.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-08163APA
Enyew Belay, Kibret; Jemal, Rebil Heiru; Tuyizere, Aloys. (2024). Innovative Glucagon-based Therapies for Obesity.. Journal of the Endocrine Society, 8(12), bvae197. https://doi.org/10.1210/jendso/bvae197
MLA
Enyew Belay, Kibret, et al. "Innovative Glucagon-based Therapies for Obesity.." Journal of the Endocrine Society, 2024. https://doi.org/10.1210/jendso/bvae197
RethinkPeptides
RethinkPeptides Research Database. "Innovative Glucagon-based Therapies for Obesity." RPEP-08163. Retrieved from https://rethinkpeptides.com/research/enyew-2024-innovative-glucagonbased-therapies-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.